Breaking Finance News

RBC Capital Markets reiterated Shire PLC (LON:SHP) to Outperform in a report released today.

RBC Capital Markets has reiterated Shire PLC (LON:SHP) to Outperform in a report released on 07/07/2017.

Previously on Thursday July 06, 2017, HSBC reported on Shire PLC (LON:SHP) held steady the target price at 4,450.00GBX. At the time, this indicated a possible upside of 0.04%.

Yesterday Shire PLC (LON:SHP) traded -1.78% lower at 4,292.00GBX. The company’s 50-day moving average is 4,206.00GBX and its 200-day moving average is 4,523.73GBX. The last closing price is down -15.83% from the 200-day moving average, compared to the S&P 500 which has increased 0.05% over the same time. 2,245,101 shares of the stock were exchanged, down from an average trading volume of 2,606,930

See Chart Below


Shire PLC has a 52 week low of 3,799.50GBX and a 52 week high of 5,377.00GBX with a P/E ratio of 51.11 The company’s market cap is currently 0 GBX.

In addition to RBC Capital Markets reporting its target price, a total of 18 brokers have issued a report on the stock. The consensus target price is 73.73GBX with 6 brokers rating the stock a strong buy, 16 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Shire PLC (LON:SHP)

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.